Dublin, Jan.23, 2026 – The global market for allergy diagnostics and therapeutics is poised for significant expansion, jumping from $36.33 billion in 2025 to a projected $57.62 billion by 2031,representing a compound annual growth rate of 7.99%.
Rising Allergies Fuel Market Growth
Table of Contents
The allergy diagnostics and therapeutics market is expanding rapidly due to increasing allergy prevalence and advancements in treatment and detection.
- The global allergy diagnostics and therapeutics market is expected to reach $57.62 billion by 2031.
- Increasing urbanization and pollution levels are key drivers of market growth.
- high treatment costs and limited insurance coverage pose significant challenges.
- Innovations in immunotherapy and diagnostics are transforming allergy management.
This sector encompasses a wide range of medical tools,tests,and medications designed to pinpoint and manage allergic reactions. The increasing number of people worldwide suffering from conditions like allergic rhinitis and food allergies is a primary driver of this growth, as these conditions require tailored medical approaches. Furthermore, growing urban populations and worsening pollution are intensifying exposure to allergens, expanding the pool of patients needing care.
Challenges to Market Expansion
Despite the positive outlook, the market faces hurdles due to the substantial costs of immunotherapy and advanced diagnostic tests. These expenses can limit access to care, particularly in developing countries. Insufficient insurance coverage further exacerbates this issue.
This segment is significant. Thermo Fisher Scientific’s ‘2024 Annual Report’ from April 2025 noted that its Specialty Diagnostics business generated $4.51 billion in revenue, demonstrating strong global investment in advanced diagnostic tools.
Emerging Trends in Allergy Management
Wearable biosensors for real-time allergen detection are transforming preventative care by allowing consumers to identify dietary and environmental triggers outside of clinical settings. These portable devices, utilizing electrochemical sensing or molecular imprinted polymers, can detect trace allergens in food and air, providing immediate reassurance. Amulet secured $5.8 million in Series A funding in August 2024, as reported by FoodBev Media, to scale its technology for testing common allergens like gluten and peanuts on the go.
Furthermore, the development of microbiome-based therapies represents a shift towards addressing the underlying imbalances in gut bacteria that contribute to allergic hypersensitivity. This approach focuses on live biotherapeutic products (LBPs) aimed at restoring gut microbial diversity to modulate immune responses and potentially prevent the development of allergies in early life. Siolta Therapeutics raised $12 million in March 2024, as reported by BioSpace, to advance its lead candidate, STMC-103H, a biotherapeutic designed to prevent food allergies and atopic dermatitis in newborns.
Key Players in the Market
- Thermo Fisher Scientific, Inc.
- R-Biopharm AG
- DASIT Group SPA
- AGILUS DIAGNOSTICS LTD.
- AESKU.GROUP gmbh
- bioMerieux SA
- Siemens Healthineers AG
- STALLERGENES GREER International AG
- HYCOR Biomedical, LLC
- Minaris Medical America, Inc.
